SG11201901070YA - Formulations for oral administration of active agents - Google Patents
Formulations for oral administration of active agentsInfo
- Publication number
- SG11201901070YA SG11201901070YA SG11201901070YA SG11201901070YA SG11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA SG 11201901070Y A SG11201901070Y A SG 11201901070YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- jerusalem
- street
- pct
- oral administration
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 241000209027 Ilex aquifolium Species 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 238000004503 metal oxide affinity chromatography Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- UQFYDAAKCZKDHS-UHFFFAOYSA-M sodium;4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate Chemical compound [Na+].OC1=CC(Cl)=CC=C1C(=O)NCCCC([O-])=O UQFYDAAKCZKDHS-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
GSG • Pize - na \"Thti- - 1.5 mg - Pterse TH(1-34) - a5373g' 3 Sa-t.gm calcium - 1.3r • , C8;Ckifn - L 20D .33:0 Ti me (minutes) FIG. 5 1Ca W O 20 18/0339 27 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 February 2018 (22.02.2018) WIP0 I PCT 0111111010 0111 °nolo olimin omoi Holm° oimIE (10) International Publication Number WO 2018/033927 Al (51) International Patent Classification: A61K 38/29 (2006.01) A61P 19/08 (2006.01) A61K 9/20 (2006.01) A61K 31/195 (2006.01) A61P 19/10 (2006.01) (21) International Application Number: PCT/IL2017/050920 (22) International Filing Date: 17 August 2017 (17.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/375,989 17 August 2016 (17.08.2016) US (71) Applicant: ENTERA BIO LTD. [IL/IL]; Jerusalem Bio Park, Hadassah Ein-Kerem, P.O. Box 12117, 9112002 Jerusalem (IL). (72) Inventors: BURSHTEIN, Gregory; 71/8 Kislev Street, 7177625 Modiin (IL). ROTHNER, Ariel; 13a Gideon Street, Apt. 16, 9350614 Jerusalem (IL). SCHWARTZ, Phillip M.; 36/5 Rachel Imenu Street, 9322823 Jerusalem (IL). GALITZER, Hillel; 43 Slav Street, 7681200 Yad Binyamin (IL). (74) Agent: EHRLICH, Gal et al.; G. E. EHRLICH (1995) LTD., 11 Menachem Begin Road, 5268104 Ramat Gan (IL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (54) Title: FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS (57) : Pharmaceutical compositions comprising a therapeutically active agent and an absorption enhancer such as NAC, NAD, 5-CNAC, 4-MOAC, 4-CNAB or a salt thereof, for use in the treatment of a condition treatable by said therapeutically active agent, are provided. The compositions are for concomitant oral administration of two or more of the unit dosage form, which form together a therapeutically effective amount of the therapeutically active agent and an effective amount of the absorption enhancer. Multi-dose compositions comprising the two or more of the unit dosage form are also provided. [Continued on next page] WO 2018/033927 Al MIDEDIM011111 11111111E10101011101001101010ERVOIS MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662375989P | 2016-08-17 | 2016-08-17 | |
| PCT/IL2017/050920 WO2018033927A1 (en) | 2016-08-17 | 2017-08-17 | Formulations for oral administration of active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901070YA true SG11201901070YA (en) | 2019-03-28 |
Family
ID=61196521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901070YA SG11201901070YA (en) | 2016-08-17 | 2017-08-17 | Formulations for oral administration of active agents |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190209657A1 (en) |
| EP (1) | EP3500291A4 (en) |
| JP (3) | JP2019524836A (en) |
| KR (2) | KR20190039768A (en) |
| CN (4) | CN116831978A (en) |
| AU (1) | AU2017311698A1 (en) |
| BR (1) | BR112019003136A2 (en) |
| CA (1) | CA3033259A1 (en) |
| IL (2) | IL312218A (en) |
| MX (1) | MX2019001850A (en) |
| NZ (1) | NZ751668A (en) |
| SG (1) | SG11201901070YA (en) |
| WO (1) | WO2018033927A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283258B2 (en) | 2015-02-09 | 2023-11-01 | Entera Bio Ltd | Treatment of hypoparathyroidism |
| AR117118A1 (en) * | 2018-11-19 | 2021-07-14 | Receptor Holdings Inc | N-ACILATED FATTY AMINO ACIDS TO REDUCE THE ABSORPTION VARIABILITY IN CANNABINOID-BASED COMPOSITIONS |
| US20230172866A1 (en) * | 2020-03-18 | 2023-06-08 | Sichuan Haisco Pharmaceutical Co., Ltd. | Oral pharmaceutical composition |
| WO2023161936A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone |
| WO2023161933A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone |
| WO2023161934A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of active agents |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1606434A (en) * | 2001-12-19 | 2005-04-13 | 株式会社三和化学研究所 | Release control type formed product |
| EP1643978A1 (en) * | 2003-07-04 | 2006-04-12 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP2008520726A (en) * | 2004-11-19 | 2008-06-19 | スミスクライン・ビーチャム・コーポレイション | Pharmaceutical products |
| WO2006076692A1 (en) * | 2005-01-12 | 2006-07-20 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| US20080153779A1 (en) * | 2005-02-01 | 2008-06-26 | Jun Liao | Gastric Retention and Controlled Release Delivery System |
| WO2007061829A2 (en) * | 2005-11-17 | 2007-05-31 | Novartis Ag | Pharmaceutical composition |
| US8927015B2 (en) * | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| IT1393244B1 (en) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | SYSTEM FOR THE RELEASE TO COLON OF SUSCEPTIBLE DRUGS OF ENZYMATIC DEGRADATION AND / OR SHORTLY ABSORBED IN THE GASTROINTESTINAL TRACT |
| US9186412B2 (en) * | 2008-08-18 | 2015-11-17 | Entera Bio Ltd. | Methods and compositions for oral administration of insulin |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| CN104487056A (en) * | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | Tablet formulation comprising a peptide and a delivery agent |
| IL283258B2 (en) * | 2015-02-09 | 2023-11-01 | Entera Bio Ltd | Treatment of hypoparathyroidism |
-
2017
- 2017-08-17 AU AU2017311698A patent/AU2017311698A1/en active Pending
- 2017-08-17 BR BR112019003136A patent/BR112019003136A2/en unknown
- 2017-08-17 MX MX2019001850A patent/MX2019001850A/en unknown
- 2017-08-17 JP JP2019508963A patent/JP2019524836A/en active Pending
- 2017-08-17 IL IL312218A patent/IL312218A/en unknown
- 2017-08-17 CN CN202311014662.XA patent/CN116831978A/en active Pending
- 2017-08-17 CA CA3033259A patent/CA3033259A1/en active Pending
- 2017-08-17 CN CN202311018541.2A patent/CN116850132A/en active Pending
- 2017-08-17 SG SG11201901070YA patent/SG11201901070YA/en unknown
- 2017-08-17 IL IL264880A patent/IL264880B1/en unknown
- 2017-08-17 US US16/326,213 patent/US20190209657A1/en active Pending
- 2017-08-17 CN CN201780064008.6A patent/CN109862906A/en active Pending
- 2017-08-17 KR KR1020197007250A patent/KR20190039768A/en not_active IP Right Cessation
- 2017-08-17 WO PCT/IL2017/050920 patent/WO2018033927A1/en unknown
- 2017-08-17 KR KR1020237019713A patent/KR20230088854A/en not_active IP Right Cessation
- 2017-08-17 NZ NZ751668A patent/NZ751668A/en unknown
- 2017-08-17 EP EP17841226.8A patent/EP3500291A4/en active Pending
- 2017-08-17 CN CN202311014654.5A patent/CN116831977A/en active Pending
-
2022
- 2022-06-21 JP JP2022099609A patent/JP2022126766A/en active Pending
-
2024
- 2024-02-06 JP JP2024016436A patent/JP2024054222A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116850132A (en) | 2023-10-10 |
| AU2017311698A1 (en) | 2019-04-04 |
| JP2024054222A (en) | 2024-04-16 |
| MX2019001850A (en) | 2019-05-15 |
| US20190209657A1 (en) | 2019-07-11 |
| JP2019524836A (en) | 2019-09-05 |
| KR20230088854A (en) | 2023-06-20 |
| EP3500291A1 (en) | 2019-06-26 |
| IL312218A (en) | 2024-06-01 |
| JP2022126766A (en) | 2022-08-30 |
| IL264880A (en) | 2019-04-30 |
| NZ751668A (en) | 2022-07-29 |
| EP3500291A4 (en) | 2020-03-11 |
| KR20190039768A (en) | 2019-04-15 |
| CN116831978A (en) | 2023-10-03 |
| IL264880B1 (en) | 2024-05-01 |
| CN116831977A (en) | 2023-10-03 |
| WO2018033927A1 (en) | 2018-02-22 |
| BR112019003136A2 (en) | 2019-05-21 |
| CN109862906A (en) | 2019-06-07 |
| CA3033259A1 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901070YA (en) | Formulations for oral administration of active agents | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808003RA (en) | Bromodomain inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201804721SA (en) | Modulators of complement activity | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201907159SA (en) | Treatment of hidradenitis suppurativa | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| SG11201900651PA (en) | Combination of fxr agonists |